Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Towa Pharmaceutical Co ( (JP:4553) ) has issued an announcement.
Towa Pharmaceutical has released its Integrated Report 2024, highlighting the company’s efforts to enhance corporate value through overseas business synergies and reliability initiatives. The report also outlines Towa’s 6th Medium-term Business Plan, PROACTIVE III, for 2024-2026, focusing on expanding global manufacturing and quality control, aligning with global standards to strengthen its industry positioning and stakeholder confidence.
More about Towa Pharmaceutical Co
Towa Pharmaceutical Co is a company in the pharmaceutical industry that focuses on creating superior products and services to contribute to people’s health. The company aims to be valued and needed by patients, healthcare professionals, and local communities, with a strong emphasis on supporting health and genuine smiles.
YTD Price Performance: 0.59%
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.05B
For detailed information about 4553 stock, go to TipRanks’ Stock Analysis page.